DecImmune Therapeutics Lands $1,000,000 New Funding Round

  • Feed Type
  • Date
  • Company Name
    DecImmune Therapeutics
  • Mailing Address
    One Blackfan Circle Rm. 10217 Boston, MA 02115
  • Company Description
    The company operates as a drug development company focused on inflammation.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    The new funds will enable accelerated development of the company’s proprietary technology to reduce tissue damage, accelerate healing, and improve outcomes associated with ischemia reperfusion injury.
  • M&A Terms
  • Venture Investor
    Astellas Venture Management LLC
  • Venture Investor
    HealthCare Ventures
  • Venture Investor
    Amgen Ventures

Trending on Xconomy